LJAC
ARQT icon

L.J. Altfest & Co’s Arcutis Biotherapeutics ARQT Stock Holding History

L.J. Altfest & Co’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,830
Closed -$373K – 334
2025
Q4 		$373K Sell
12,830
-3,882
-23% -$99.4K 0.04% 259
2025
Q3 		$315K Buy
+16,712
New +$264K 0.04% 279
2025
Q1 		– Sell
-14,455
Closed -$201K – 326
2024
Q4 		$201K Buy
14,455
+47
+0.3% +$515 0.03% 313
2024
Q3 		$134K Buy
+14,408
New +$142K 0.02% 325

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return